estramustine (emcyt) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard moiety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$12.0014 - $16.0324
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

17beta-estradiol 3-(bis(2-chloroethyl)carbamate) | 17β-estradiol 3-(bis(2-chloroethyl)carbamate) | emcyt | estracty | estracyt | estradiol 3-(n,n-bis(2-chloroethyl)carbamate) | estramustina | estramustine | estramustine phosphate | estramustine phosphate sodium | estramustinum | ro-218837001 | ro-218837-001 | ro-222296000 | ro-22-2296000

Organizations (50)

Research & Development (49)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (2)


 

Carcinoma

Prostatic Neoplasms (approved 1991)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Breast Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1/Phase 2)

Lymphoma (Phase 2)

Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 3)

Sarcoma (Phase 1/Phase 2)

Thromboembolism (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 51
  • # of Trial Organizations: 49

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue